Outlook Therapeutics (OTLK) Total Liabilities (2015 - 2026)
Outlook Therapeutics (OTLK) posted quarterly Total Liabilities of $50.9 million for Q1 2026, down 1.26% year-over-year from $51.5 million in Q1 2025, and down 10.39% quarter-over-quarter from $56.8 million in Q4 2025.
Outlook Therapeutics (OTLK) Total Liabilities (2015 - 2026) Analysis & Trends
Outlook Therapeutics (OTLK) has reported Total Liabilities for 12 consecutive years, with $50.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Liabilities fell 1.26% year-over-year to $50.9 million; the TTM figure through Mar 2026 stood at $50.9 million (down 1.26% YoY), while the FY2025 annual figure was $50.8 million, down 50.17% from the prior year.
- Total Liabilities retreated to $50.9 million in Q1 2026 per OTLK's latest filing, from $56.8 million in the prior quarter.
- Across five years, Total Liabilities topped out at $193.3 million in Q1 2024 and bottomed at $18.5 million in Q2 2022.
- Historically, Total Liabilities has averaged $62.7 million across 5 years, with a median of $50.8 million in 2025.
- Annual changes were most pronounced in 2024 — Total Liabilities surged 343.92% — and 2025, when it slumped 73.33%.
- Outlook Therapeutics' Total Liabilities stood at $46.9 million in 2022, then declined by 1.92% to $46.0 million in 2023, then surged by 46.21% to $67.3 million in 2024, then retreated by 15.62% to $56.8 million in 2025, then fell by 10.39% to $50.9 million in 2026.
- Business Quant data shows OTLK's Total Liabilities at $50.9 million in Q1 2026, $56.8 million in Q4 2025, and $50.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.35 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 10.03 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 3.22 Bn |
| 10 | Outlook Therapeutics | 93.64 Mn | 82.40 Mn | -8,265.00 | 36.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 50.89 Mn |
| Dec 31, 2025 | 56.79 Mn |
| Sep 30, 2025 | 50.77 Mn |
| Jun 30, 2025 | 59.58 Mn |
| Mar 31, 2025 | 51.54 Mn |
| Dec 31, 2024 | 67.30 Mn |
| Sep 30, 2024 | 101.90 Mn |
| Jun 30, 2024 | 130.77 Mn |
| Mar 31, 2024 | 193.26 Mn |
| Dec 31, 2023 | 46.03 Mn |
| Sep 30, 2023 | 46.74 Mn |
| Jun 30, 2023 | 49.95 Mn |
| Mar 31, 2023 | 43.54 Mn |
| Dec 31, 2022 | 46.93 Mn |
| Sep 30, 2022 | 19.79 Mn |
| Jun 30, 2022 | 18.51 Mn |
| Mar 31, 2022 | 31.72 Mn |
| Dec 31, 2021 | 29.85 Mn |
| Sep 30, 2021 | 18.20 Mn |
| Jun 30, 2021 | 20.13 Mn |